汗液化物反映了CFTR功能,并且与CFTR调节器治疗后的临床结果相关
Edith T Zemanick1, Bonnie Ramsey2, Dorota Sands3
1Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO, USA.
概括
用CFTR调节器治疗的囊性纤维化患者的低汗液化物水平与改善的健康结果相关. 这支持将CFTR功能和汗液化物水平正常化的目标,以获得更好的临床结果.
科学领域:
- 生物医学研究生物医学研究
- 肺部病理学 肺部病理学
- 遗传学 是一个遗传学.
背景情况:
- 囊性纤维化 (CF) 是一种影响多个器官的遗传性疾病.
- CFTR调节器是治疗CF的有效方法,改善CFTR蛋白的功能.
- 需要澄清CFTR功能测量 (例如,汗液化物) 与调节剂的临床结果之间的联系.
研究的目的:
- 调查汗液化物水平与体外CFTR功能之间的关系.
- 分析接受CFTR调节剂的CF患者的汗液化物水平和临床结果之间的关联.
主要方法:
- 在健康个体,携带者和CF患者的汗水化物与在体外HBE细胞化物运输调节器上的汗水化物进行比较.
- 进行了第三期试验的综合分析,评估汗液化物与肺功能,BMI,患者报告的结果和恶化.
主要成果:
- 在体内,汗液化物与体内依赖CFTR的化物流有很强的相关性.
- 在使用调节器的CF患者中,较低的汗液化物水平 (<60 mmol/L) 与较高水平 (≥60 mmol/L) 相比,与更好的临床结果有关.
结论:
- 降低的汗液化物水平表明CFTR功能得到增强,并且与使用调节器的CF患者的更好的临床结果有关.
- 这些发现支持治疗努力使CFTR功能正常化,旨在使汗液化物水平低于诊断值 (<60 mmol/L) 和理想的正常水平 (<30 mmol/L).
更多相关视频
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.2K
15:12Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
Published on: May 10, 2014
14.5K
相关概念视频
01:23Cystic Fibrosis: Pathogenesis
185
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
185
01:24Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139